clinical trial · NCT04649242
Randomized Study in Children and Adolescents With Migraine: Acute Treatment
Pediatric MigraineRimegepant/BHV3000Matching placebo
brief summary
The purpose of this study is to test the safety and efficacy of BHV-3000 versus placebo in the acute treatment of moderate or severe migraine in children and adolescents.
started
Jan 15, 2021
primary completion
Jan 9, 2029
completion
Jan 9, 2029
last updated
Jul 1, 2026
official title
Phase 3, Multicenter, Randomized, Double-blind, Group Sequential, Placebo-controlled Study to Assess Efficacy and Safety of Rimegepant for the Treatment of Migraine (With or Without Aura) in Children and Adolescents ≥ 6 to < 18 Years of Age
sourced from ClinicalTrials.gov · pharmadog mirrors structured fields, not the full protocol